• TACTI-002 patient recruitment update
• Six patients now enrolled and dosed in INSIGHT-004, 6 mg cohort complete
• Significant eftilagimod alpha clinical data expected in coming months:
o AIPAC Phase II - data expected in Q1 calendar year 2020
o TACTI-002 Phase II - data at SITC in Nov 2019 and in Q1 in 2020
o TACTI-mel Phase I - final safety data expected in H1 2020
o INSIGHT-004 Phase I - initial safety data expected in Q4 calendar year 2019
• Scale up to 2,000L for commercial manufacturing started
• Solid financial position following receipt of $7.4m GSK milestone payment, with expected cash runway at least to the end of calendar year 2020, well beyond above data catalysts
- Forums
- ASX - By Stock
- IMM
- Ann: Operational Update
Ann: Operational Update, page-2
-
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M |
Open | High | Low | Value | Volume |
36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 133736 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.355 |
2 | 9500 | 0.350 |
4 | 199315 | 0.345 |
10 | 84868 | 0.340 |
2 | 10985 | 0.335 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 96182 | 4 |
0.365 | 81517 | 4 |
0.370 | 150545 | 8 |
0.375 | 156434 | 4 |
0.380 | 167642 | 11 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |